Investing Profile

Kush Parmar

InvestorVC
Managing Partner at 5AM Ventures
5amventures.comBoston, Massachusetts
Photo of Kush Parmar, Managing Partner at 5am Ventures
Your Intro Paths to Kush Parmar

Signal uses Gmail to reveal intro paths. Email content is never read.

Sign in with Google →
Networks Kush is a member of
Moving Capital Network
963 CONNECTIONS
Moving Capital Network
963 CONNECTIONS
Harvard University Network
763 CONNECTIONS
Massachusetts Institute of Technology Network
517 CONNECTIONS
Princeton University Network
314 CONNECTIONS

Find Kush Parmar on

cb
Current Investing Position
5am Ventures Managing Partner
Investment Range
$100K - $5.0M
Sweet Spot
$1.5M
Investments On Record
20

Kush Parmar is on these Sector & Stage Rankings

Kush Parmar's Investments On Record (8)

CompanyStageDateRound SizeTotal Raised
Precede Biosciences
Series BJan 2026$64M
Series AOct 2023$57M
$120M
Co-investors: Wouter Meuleman (Illumina Ventures)
ProLynx
Series ADec 2025$70M
$70M
Co-investors: Peter Thompson (OrbiMed)
Ensoma
Series UnknownSep 2025$53M
Series BJan 2023$85M
Series AFeb 2021$70M
$260M
Co-investors: Stephen Knight (F-Prime Capital Partners), Mark Chin (Jmi Equity), Kouki Harasaki (M12 - Microsoft's Venture Fund)
Vor Biopharma
Series BJul 2020$110M
Series AFeb 2019$42M
$210M
Co-investors: Reid Hoffman (Greylock)
Akouos
Series BMar 2020$110M
Series AAug 2018$50M
SeedNov 2017$8M
$160M
Co-investors: Ed Mathers (New Enterprise Associates (NEA)), Heather Preston (Oxonian Ventures )
Cleave Therapeutics
Series CAug 2019$12M
Series BAug 2016$37M
Series ANov 2011$42M
$100M
Co-investors: Carol Gallagher (New Enterprise Associates (NEA)), Andrew Schwab (5am Ventures), Peter Thompson (OrbiMed), Marc Singer (Osage University Partners), Larry Lasky (The Column Group), Robert Garland (CrowdQuest), Alfred Scheidegger (Nextech Invest)
Arvinas
Series CApr 2018$55M
Series BOct 2015$42M
Series ASep 2013$15M
$140M
Co-investors: Tim Shannon (Canaan Partners), Colleen Cuffaro (Canaan Partners), Stephen Squinto (OrbiMed), Daniel Wagner (Connecticut Innovations), Liam Ratcliffe (New Leaf Venture Partners), Andrew Levin (RA Capital Management), Jakob Loven (Nextech Invest), Martin Alexander Gershon (Endeavor Venture Funds)
Audentes Therapeutics
Series COct 2015$65M
Series BDec 2014$43M
Series AJul 2013$30M
$140M
Co-investors: Jonathan Silverstein (OrbiMed), Stephen Squinto (OrbiMed), Jonathan Leff (Deerfield Management), Tom Woiwode (Versant Ventures)

Kush Parmar's Experience

Board Observer Envoy Therapeutics, Inc.Present
Board Observer AchaogenPresent
Kauffman Fellow, Class 16 Kauffman FellowsPresent
Board Observer and Acting VP, Strategy and Corporate Development Novira TherapeuticsPresent
Board Of Directors Audentes TherapeuticsPresent
Board of Directors ArvinasPresent
Board Of Directors Astellas PharmaPresent
Board of Directors scPharmaceuticalsPresent
Member, Scientific Advisory Board Grace Science FoundationPresent
Member, Scientific Advisory Board Grace Science, LLCPresent
Advisory Council, Department of Molecular Biology Princeton UniversityPresent
Advisory Council, Department of Molecular Biology Princeton University Investment CompanyPresent
Chairman Of The Board Of Directors Entrada TherapeuticsPresent
Board Of Directors AkouosPresent
Research Council Member Penn Medicine, University of Pennsylvania Health SystemPresent
Board Of Directors RallybioPresent
Chairman Vor BiopharmaPresent
Chairman Vor BioPresent
Board Member EnsomaPresent
Chairman ProLynxPresent
Founder, President Moving CapitalPresent
Managing Partner 5AM VenturesPresent
Founding CEO, Chairman Homology Medicines, Inc.Present
Co-Founder Immuneel Therapeutics, Ltd.Present
Co-Founder Moving CapitalPresent

Kush Parmar's Education

Princeton University A.B. Molecular Biology, Medieval Studies
Massachusetts Institute of Technology M.D. HST Program
Harvard University Ph.D. Biomedical Sciences

Investors who invest with Kush Parmar

Sign in with Google →

Scouts & Angels Affiliated With Kush Parmar

Sign in with Google →